![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-300x278.jpg)
![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-e1629971959212.jpg)
news
Lilly outlines $1bn India manufacturing expansion
The investment will cover CMO collaborations and a new manufacturing…
The investment will cover CMO collaborations and a new manufacturing and quality hub in Hyderabad.
List view / Grid view
Patrik Jonsson
news
Lilly wins European Alzheimer’s approval for Kisunla after regulatory setbacks
The anti-amyloid monoclonal antibody is part of the class of…
The anti-amyloid monoclonal antibody is part of the class of medicines representing the first disease-modifying therapies for the neurodegenerative disease.
news
Lilly announces leadership changes and creation of new business units
Eli Lilly and Company have announced executive leadership changes and…
Eli Lilly and Company have announced executive leadership changes and the creation of neuroscience and immunology business units.
news
Baricitinib and remdesivir reduce time to recovery in COVID-19 patient trial
A study of baricitinib in combination with remdesivir has met…
A study of baricitinib in combination with remdesivir has met its primary endpoint in COVID-19 patients, by reducing time to recovery in comparison with only remdesivir.
news
Lilly enrols first COVID-19 patient in Phase III study to test baricitinib
A Phase III trial has been launched to study whether…
A Phase III trial has been launched to study whether baricitinib, an oral JAK1/JAK2 inhibitor, is effective at combatting COVID-19 in hospitalised patients.
news
Lilly announces agreement to acquire Dermira for $1.1bn
Eli Lilly has announced it is to acquire Dermira for $18.75 per…
Eli Lilly has announced it is to acquire Dermira for $18.75 per share, or approximately $1.1 billion, which will expand Lilly's immunology pipeline.
news
Eli Lilly to acquire biopharma company Dermira for $1.1bn
According to Eli Lilly, the company will acquire Dermira in…
According to Eli Lilly, the company will acquire Dermira in an all-cash transaction for $1.1 billion, at a rate of $18.75 per share.
